ArticleCancer biology & therapy2016
Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration.
Article in Cancer biology & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 58 citations in OpenAlex.
- Prognostic Factors in Patients with Peritoneal Mesothelioma Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Systematic Review and Meta-Analysis.Annals of surgical oncology · 2026Article
- Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma.NPJ precision oncology · 2026Article
- Mesothelioma location influences the tumour microenvironment and immune checkpoint therapy response in preclinical models.Scientific reports · 2026Article
- Use of Neoadjuvant Immunotherapy in Malignant Peritoneal Mesothelioma as a Bridge to Surgical Intervention: A Case Report.The American journal of case reports · 2025Article
- Therapeutic Strategies to Improve the Treatment of Pleural Mesothelioma.Current medicinal chemistry · 2025Review
- Malignant peritoneal mesothelioma interactome with 417 novel protein-protein interactions.BJC reports · 2024Article
- The MexTAg collaborative cross: host genetics affects asbestos related disease latency, but has little influence once tumours develop.Frontiers in toxicology · 2024Article
- Genomic landscape of pleural and peritoneal mesothelioma tumours.British journal of cancer · 2022Article
- Molecular Pathways in Peritoneal Mesothelioma: A Minireview of New Insights.Frontiers in oncology · 2022Review
- Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma.Cancer discovery · 2021Article
- Clinical Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Malignant Peritoneal Mesothelioma.JAMA network open · 2021Article
- New insights in the pathology of peritoneal surface malignancy.Journal of gastrointestinal oncology · 2021Review
- Malignant pleural mesothelioma: an update.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2021Review
- Molecular characterization of diffuse malignant peritoneal mesothelioma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- The Molecular Basis of Malignant Pleural Mesothelioma.Thoracic surgery clinics · 2020Review
- Genomics and Functional Genomics of Malignant Pleural Mesothelioma.International journal of molecular sciences · 2020Review
- Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival.Molecular oncology · 2020Article
- CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.BMC cancer · 2019Article
- Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response.Cold Spring Harbor molecular case studies · 2019Article
- Genomic Deletion ofInternational journal of molecular sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Malignant mesothelioma (MM) is an aggressive tumor arising from mesothelial linings of the serosal cavities. Pleural space is the most common site, accounting for about 80% of cases, while peritoneum makes up the majority of the remaining 20%. While histologically similar, tumors from these sites are epidemiologically and clinically distinct and their attribution to asbestos exposure differs. We compared DNA array-based findings from 48 epithelioid peritoneal MMs and 41 epithelioid pleural MMs to identify similarities and differences in copy number alterations (CNAs). Losses in 3p (BAP1 gene), 9p (CDKN2A) and 22q (NF2) were seen in tumors from both tumor sites, although CDKN2A and NF2 losses were seen at a higher rate in pleural disease (p<0.01). Overall, regions of copy number gain were more common in peritoneal MM, whereas losses were more common in pleural MM, with regions of loss containing known tumor suppressor genes and regions of gain encompassing genes encoding receptor tyrosine kinase pathway members. Cases with known asbestos causation (n = 32 ) were compared with those linked to radiation exposure (n = 9 ). Deletions in 6q, 14q, 17p and 22q, and gain of 17q were seen in asbestos-associated but not radiation-related cases. As reported in post-radiation sarcoma, gains outnumbered losses in radiation-associated MM. The patterns of genomic imbalances suggest overlapping and distinct molecular pathways in MM of the pleura and peritoneum, and that differences in causation (i.e., asbestos vs. radiation) may account for some of these site-dependent differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.